A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

681

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: Ocrelizumab

Sponsor

Hoffmann-La Roche